SkyView Investment Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

SkyView Investment Advisors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-766	Closed	-$52K	–	579
2022 Q3	$52K	Sell	766 -38	-5%	-$2.1K	0.02%	411
2022 Q2	$26K	Hold	804	–	–	0.01%	473
2022 Q1	$28K	Buy	804 +687	+587%	+$20.5K	0.01%	490
2021 Q4	$26K	Buy	+117	New	+$3.62K	0.01%	488
2021 Q3	–	Sell	-315	Closed	-$13K	–	446
2021 Q2	$13K	Hold	315	–	–	0.01%	256
2021 Q1	$13K	Buy	315 +271	+616%	+$12.5K	0.01%	264
2020 Q4	$2K	Buy	+44	New	+$2.17K	﹤0.01%	281

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

SkyView Investment Advisors's GBT Position: Q4 2022 in Review

SkyView Investment Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 766 shares — an estimated $52K sold.

SkyView Investment Advisors first reported a position in GBT in Q4 2020 and held it in 7 quarters. The position peaked at $52K in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

SkyView Investment Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
SkyView Investment Advisors sold 766 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $52K.
SkyView Investment Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 7 quarters.
SkyView Investment Advisors's Global Blood Therapeutics, Inc. position peaked at $52K in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on SkyView Investment Advisors's 13F filing for Q4 2022, filed 16 Feb 2023.